— Clinical credibility formally recognized through collaborative research with leading Taiwanese KOLs and publication in ESMO Open

IMBdx’s AlphaLiquid100, a body fluid–based liquid biopsy service, has received the 2025 SNQ (Symbol of National Quality) National Quality Mark in Taiwan, recognizing its clinical reliability and service quality.

The platform enables high-performance cfDNA analysis across multiple body fluids, including blood, pleural effusion, ascites, cerebrospinal fluid, and bronchoalveolar lavage fluid, demonstrating strong applicability in real-world clinical practice.

Through collaborative research with leading Taiwanese medical institutions and KOLs, IMBdx has built robust clinical evidence supporting the analytical performance and clinical utility of body fluid–based liquid biopsy.

These efforts culminated in the publication of a pleural effusion–based cfDNA study in ESMO Open, which showed improved detection of actionable mutations compared to conventional molecular testing, including effective identification of acquired EGFR T790M mutations in advanced NSCLC.

The SNQ certification confirms that IMBdx’s body fluid–based liquid biopsy delivers clinically validated performance as a reliable precision diagnostics service, extending beyond research into everyday patient care.

“IMBdx aims to establish liquid biopsy not merely as a diagnostic test, but as a reliable precision diagnostics infrastructure that can be trusted in everyday clinical practice.”
“The SNQ certification and the publication in ESMO Open are particularly meaningful in that they reflect a continuous and integrated accumulation of research outcomes and service quality, both focused on creating tangible value for patient care.”
“Moving forward, IMBdx will continue to expand clinical evidence based on high-quality liquid biopsy services and grow into a patient-centered global precision diagnostics company that supports cancer treatment decision-making and the entire patient journey.”